Leverage CDMO Expertise To Accelerate Biologics Development And Manufacturing

By Joon Chang, Samsung Biologics

A growing prevalence of chronic diseases and rise in the geriatric population are encouraging pharmaceutical companies to introduce biologic products to improve and expand on therapeutic options for those patients. In this quickly evolving market, drug developers must be flexible both in meeting market demand and in optimizing cost efficiencies — with effective project management, partnerships, and sustainable processes at the forefront of this effort.

To facilitate accelerated development, manufacture, and release of biologics — taking advantage of this explosive growth — drug developers have steadily increased their outsourcing budgets for key services (from CRO services to manufacturing), reducing the need for in-house capabilities.

An experienced contract manufacturer can help drug developers to better utilize valuable internal resources, leverage a deep pool of industry experience, and mitigate risk across development cycles — staying competitive in a rapidly evolving market. However, finding the right combination of services, culture, expertise, and capacity is critical. Samsung Biologics provides tailored services to meet a multitude of client needs, from niche capabilities to a full end-to-end spectrum of services (e.g., development to commercial manufacturing), across four facilities on our Bio Campus I; Bio Campus II already is underway to meet our clients’ future needs.